ENTA

SEC source: 0001062993-25-013981 · form4.xml · nonDerivative · entry 1

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,590

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022.

SEC source: 0001062993-25-005507 · form4.xml · derivative · entry 1

Vance Terry · CIK 0001572282 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2035-03-13

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

SEC source: 0001062993-25-005506 · form4.xml · derivative · entry 1

Russell Lesley · CIK 0001374636 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2035-03-13

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

SEC source: 0001062993-25-005505 · form4.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2035-03-13

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

SEC source: 0001062993-25-005503 · form4.xml · derivative · entry 1

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2035-03-13

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

SEC source: 0001062993-25-005504 · form4.xml · derivative · entry 1

Hata Yujiro S · CIK 0001649119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2035-03-13

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

SEC source: 0001062993-25-005502 · form4.xml · derivative · entry 1

CARTER BRUCE L A · CIK 0001225503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2035-03-13

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

SEC source: 0001062993-25-002225 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 846,638

F1 · kind: The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 5,142 shares, all of which related to a "sell to cover" transaction required to satisfy tax withholding obligations due as a result of settlement of a portion of a restricted stock unit award granted on November 23, 2022. The reporting person has paid to Enanta $13,861.92, representing the full amount of the profit realized in connection with the short-swing transaction.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.86, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001062993-25-002568 · form4.xml · nonDerivative · entry 2

Luu Brendan · CIK 0001842369 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,221

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002568 · form4.xml · nonDerivative · entry 1

Luu Brendan · CIK 0001842369 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,547

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-25-002563 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,479

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002563 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,805

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-25-002558 · form4.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,535

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002558 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,859

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-25-002561 · form4.xml · nonDerivative · entry 2

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,807

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002561 · form4.xml · nonDerivative · entry 1

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,668

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-25-002553 · form4.xml · nonDerivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Chief Fin. & Admin Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,884

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002553 · form4.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Chief Fin. & Admin Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,210

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-25-002549 · form4.xml · nonDerivative · entry 2

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 864,654

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002549 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 872,138

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-24-020386 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,305

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-020384 · form4.xml · nonDerivative · entry 1

Luu Brendan · CIK 0001842369 · Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,047

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-020382 · form4.xml · nonDerivative · entry 1

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,918

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-020380 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 369,109

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-020378 · form4.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Chief Fin. & Admin Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,710

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-020375 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 801,638

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-019990 · form4.xml · nonDerivative · entry 1

Luu Brendan · CIK 0001842369 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,330

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0001062993-24-019987 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,588

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0001062993-24-019982 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,700

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021.

SEC source: 0001062993-24-019980 · form4.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Chief Fin. & Admin Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,301

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021.

SEC source: 0001062993-24-019974 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 806,780

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021.

SEC source: 0001062993-24-019776 · form4.xml · derivative · entry 1

Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-019774 · form4.xml · derivative · entry 1

Luu Brendan · CIK 0001842369 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-019772 · form4.xml · derivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-019770 · form4.xml · derivative · entry 1

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-019768 · form4.xml · derivative · entry 1

Or Yat Sun · CIK 0001571212 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-019766 · form4.xml · derivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Chief Fin. & Admin Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-019764 · form4.xml · derivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-014792 · form4.xml · nonDerivative · entry 2

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,784

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022.

SEC source: 0001062993-24-013820 · form4.xml · derivative · entry 5

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,625

Underlying: Common Stock · 5,375 shares

Expires 2033-11-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).

SEC source: 0001062993-24-013820 · form4.xml · nonDerivative · entry 4

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,717

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive.

SEC source: 0001062993-24-013820 · form4.xml · nonDerivative · entry 3

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-24-013820 · form4.xml · nonDerivative · entry 2

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,717

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive.

SEC source: 0001062993-24-013820 · form4.xml · nonDerivative · entry 1

Rottinghaus Scott T. · CIK 0001942407 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,988

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive.

SEC source: 0001062993-24-012734 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,341

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.54, inclusive.

SEC source: 0001062993-24-009175 · form4.xml · derivative · entry 1

Kowalsky Matthew Paul · CIK 0001705824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-04-29

F1 · derivative.exercise_date: Twenty-five percent (25%) of such option will become exercisable on April 29, 2025 (the "Anniversary Date"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment).

SEC source: 0001062993-24-006052 · form4.xml · derivative · entry 1

Vance Terry · CIK 0001572282 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2034-03-06

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.

SEC source: 0001062993-24-006050 · form4.xml · derivative · entry 1

Russell Lesley · CIK 0001374636 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2034-03-06

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.

SEC source: 0001062993-24-006046 · form4.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2034-03-06

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.

SEC source: 0001062993-24-006042 · form4.xml · derivative · entry 1

Hata Yujiro S · CIK 0001649119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,700

Underlying: Common Stock · 15,700 shares

Expires 2034-03-06

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.